SynthesisClinical genitourinary cancer2014

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

Neeraj Agarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.